Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $19.22 Million
Brokerages forecast that Clovis Oncology, Inc. (NASDAQ:CLVS) will post $19.22 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Clovis Oncology’s earnings, with the lowest sales estimate coming in at $18.61 million and the highest estimate coming in at $20.00 million. Clovis Oncology posted sales of $80,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 23,925%. The business is scheduled to issue its next earnings report on Wednesday, February 28th.
On average, analysts expect that Clovis Oncology will report full-year sales of $19.22 million for the current year, with estimates ranging from $55.27 million to $58.47 million. For the next year, analysts forecast that the business will report sales of $209.03 million per share, with estimates ranging from $168.20 million to $279.59 million. Zacks’ sales calculations are an average based on a survey of analysts that cover Clovis Oncology.
Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.06). The company had revenue of $16.81 million for the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same period in the prior year, the business posted ($1.70) earnings per share.
CLVS has been the topic of a number of analyst reports. Zacks Investment Research upgraded Clovis Oncology from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research report on Tuesday, October 17th. Cann restated a “hold” rating on shares of Clovis Oncology in a research report on Monday, September 11th. Oppenheimer restated a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, October 10th. BidaskClub upgraded Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Finally, Leerink Swann restated an “outperform” rating and set a $90.00 target price (down from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the stock. Clovis Oncology has an average rating of “Buy” and an average target price of $91.83.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $84.54, for a total value of $253,620.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00. Following the completion of the transaction, the director now directly owns 25,618 shares in the company, valued at $1,537,080. The disclosure for this sale can be found here. Insiders sold a total of 13,500 shares of company stock worth $907,200 over the last ninety days. 12.50% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the stock. Phocas Financial Corp. purchased a new position in Clovis Oncology in the 2nd quarter valued at about $112,000. Capital Analysts LLC purchased a new position in Clovis Oncology in the 3rd quarter valued at about $111,000. Advisors Asset Management Inc. lifted its stake in Clovis Oncology by 160.7% in the 2nd quarter. Advisors Asset Management Inc. now owns 1,895 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 1,168 shares in the last quarter. Cypress Capital Management LLC WY lifted its stake in Clovis Oncology by 272.7% in the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new position in Clovis Oncology in the 2nd quarter worth approximately $257,000.
Shares of Clovis Oncology (CLVS) traded down $1.23 on Tuesday, reaching $66.49. The company’s stock had a trading volume of 790,800 shares, compared to its average volume of 1,130,000. The firm has a market cap of $3,260.00, a P/E ratio of -8.03 and a beta of 1.38. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology has a 12 month low of $43.52 and a 12 month high of $99.45.
COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate Clovis Oncology, Inc. (CLVS) Will Announce Quarterly Sales of $19.22 Million” was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2018/01/05/brokerages-anticipate-clovis-oncology-inc-clvs-will-announce-quarterly-sales-of-19-22-million.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.